Your browser doesn't support javascript.
loading
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders.
Nugent, Diane; Acharya, Suchitra S; Baumann, Kimberly J; Bedrosian, Camille; Bialas, Rebecca; Brown, Kai; Corzo, Deya; Haidar, Amar; Hayward, Catherine P M; Marks, Peter; Menegatti, Marzia; Miller, Margaret E; Nammacher, Kate; Palla, Roberta; Peltier, Skye; Pruthi, Rajiv K; Recht, Michael; Sørensen, Benny; Tarantino, Michael; Wolberg, Alisa S; Shapiro, Amy D.
Afiliación
  • Nugent D; Center for Inherited Blood Disorders, Orange, California, USA.
  • Acharya SS; Pediatric Hematology Division, Department of Pediatrics, University of California at Irvine, Children's Hospital of Orange County, Irvine, California, USA.
  • Baumann KJ; Hemostasis and Thrombosis Center, Northwell Health, New Hyde Park, New York, New York, USA.
  • Bedrosian C; Center for Bleeding and Clotting Disorders, M Health Fairview, Minneapolis, Minnesota, USA.
  • Bialas R; Ultragenyx Pharmaceutical Inc Novato, California, USA.
  • Brown K; Plasminogen Deficiency Foundation, Durham, North Carolina, USA.
  • Corzo D; National Hemophilia Foundation, New York, New York, USA.
  • Haidar A; Sigilon Therapeutics, Cambridge, Massachusetts, USA.
  • Hayward CPM; Patient author, Lived Experience Expert, Dearborn, Michigan, USA.
  • Marks P; Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, Ontario, Canada.
  • Menegatti M; Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Miller ME; Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Nammacher K; Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Palla R; Oncology Support Service, Providence Alaska Medical Center, Anchorage, Alaska, USA.
  • Peltier S; National Hemophilia Foundation, New York, New York, USA.
  • Pruthi RK; Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Recht M; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
  • Sørensen B; Center for Bleeding and Clotting Disorders, M Health Fairview, Minneapolis, Minnesota, USA.
  • Tarantino M; Comprehensive Hemophilia Center, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Wolberg AS; American Thrombosis and Hemostasis Network, Rochester, New York, USA.
  • Shapiro AD; The Hemophilia Center, Oregon Health & Science University, Portland, Oregon, USA.
Expert Rev Hematol ; 16(sup1): 55-70, 2023 03.
Article en En | MEDLINE | ID: mdl-36920862
Living with an ultra-rare inherited bleeding disorder is challenging. Patients can feel alone and unsure of where to find support because their disorder is so rare. In this paper, a group of ultra-rare bleeding disorder experts, including doctors, researchers, regulators, patient advocates, and patients, identify the research that could best improve the lives of people with these disorders. They propose a national network of specialists who can help doctors, who may never have seen these disorders before, to find the right diagnosis faster. A centralized laboratory specialized in ultra-rare bleeding disorders could also improve diagnosis and do research studies. This would help us learn, for example, how symptoms change throughout a patient's life, how effective different treatments are, and what it is like for patients to live with these disorders. A second research priority is to better understand each individual disorder so that the best treatments can be chosen or developed. A pathway showing doctors which treatment options to try, in which order, would help them help their patients. The third research priority is to make it easier to study new treatments for ultra-rare bleeding disorders. This requires designing studies with very small numbers of participants, identifying meaningful outcomes to measure, and convincing pharmaceutical companies to invest in these studies. International agreement on these requirements would allow more patients to participate and benefit from the research. These top-priority research goals should greatly improve knowledge about, and diagnosis and treatment of, ultra-rare inherited bleeding disorders.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Hemofilia A / Hemorragia Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Expert Rev Hematol Asunto de la revista: HEMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Hemofilia A / Hemorragia Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Expert Rev Hematol Asunto de la revista: HEMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos